Market Context — Why This Technology, Why Now

The global oncology market is rapidly shifting towards personalized and cell-based immunotherapies, driven by demand for more effective treatments for advanced cancers and limitations of existing modalities. Regulatory bodies are increasingly streamlining approval pathways for breakthrough cell and gene therapies, creating a favorable environment for rapid market entry. This technology aligns perfectly with the trend of targeted, patient-specific treatments, offering a crucial advantage in a competitive landscape where rapid clinical impact is paramount.

Key Competitive Advantages
01

Provides immediate anti-tumor effects post-administration by directly modifying T-cells, potentially improving prognosis for advanced cancer patients.

02

Offers more effective therapeutic outcomes when combined with existing anti-cancer treatments like chemotherapy and molecular-targeted drugs, expanding treatment options.

03

Demonstrates extremely high originality with only three prior art documents cited, indicating strong potential for early market share acquisition.

Market Opportunity
Liver Cancer Treatment Market
~$400M (AI est.)
Liver cancer is a major cancer globally, and the limited treatment options for advanced stages create a strong demand for innovative technologies. This technology could complement existing treatments and improve outcomes, potentially expanding market reach.
Oncology pharmaceutical companies Biotech firms specializing in liver disease Academic medical centers focused on cancer research
Oncology Immunotherapy Market
~$6.5B (AI est.)
Following the success of immune checkpoint inhibitors, immunotherapy is becoming central to cancer treatment. TCR gene-modified T-cell therapy is a next-generation approach with high growth potential. This technology could capture significant market opportunities within this trend.
Global biopharmaceutical leaders in oncology Cell and gene therapy developers Contract research organizations (CROs) for immunotherapy trials
Regenerative Medicine & Cell Therapy Market
~$3.5B (AI est.)
Regenerative medicine and cell therapies using patient-derived cells are advancing as the ultimate form of personalized medicine. This technology, utilizing patient-derived T-cells, is expected to play a crucial role in this market segment.
Personalized medicine developers Cell therapy manufacturing specialists Hospitals and clinics offering advanced cell treatments
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the specific T-cell receptor protein, its coding polynucleotide, and methods for generating gene-modified T-cells for cancer gene therapy. It is considered robust, having successfully overcome examiner rejections, demonstrating strong novelty, inventiveness, and clear claim scope with only three prior art documents cited.

Competitive White Space

The patent's scope is focused on MRP3-targeted T-cells. White space exists in developing T-cell therapies for other specific cancer antigens or exploring alternative gene modification delivery systems for broader applicability beyond current methods.

Economic Impact
~$1.5M/year estimated medical cost reduction and QOL improvement (est.).
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming an average annual medical cost reduction of ~$6.5K (AI est.) per patient due to shortened treatment periods and recurrence suppression for advanced liver cancer. If the annual number of new HLA-A24 positive advanced liver cancer patients in Japan is 2,000, the estimated annual medical cost reduction is ~$1.5M (AI est.). Significant socioeconomic contributions from improved patient QOL are also anticipated.

Speed to Market
3× faster than in-house development
This technology is based on years of research at Kanazawa University, with an established specific binding mechanism for TCRs to MRP3-derived peptide and HLA-A24 antigen complexes. Basic technology for gene-modified T-cell production is already validated. Focusing on protocol development for clinical application could significantly shorten time-to-market compared to in-house TCR discovery and development from scratch.
Competitive Positioning

X: Rapidity of Therapeutic Effect
Y: Suitability for Personalized Therapy

Business Models & Applications
🤝 License Grant
Licensing the TCR gene-modified T-cell production technology to pharmaceutical companies and biotech ventures, entrusting clinical development, manufacturing, and sales.
🔬 Collaborative R&D
Maximizing the technology's value through joint research and development, focusing on applications to other cancer types or enhancing therapeutic efficacy.
🏭 Contract Cell Manufacturing
Providing contract manufacturing services for T-cell therapies using this technology, creating an ecosystem where licensees can offer treatments without proprietary manufacturing facilities.
Adjacent Application Opportunities
🩺 Other Cancer Treatments
Application to MRP3-Expressing Cancers
MRP3 is expressed in various cancers beyond liver cancer, including gastric, colorectal, and breast cancers. Applying this TCR technology to specifically target MRP3-expressing cancer cells could expand the treatment scope to a broader range of solid tumors, potentially addressing a multi-billion dollar market segment.
🧪 Diagnostic Development
MRP3 Expression Diagnostics & HLA Typing
Developing diagnostic kits to assess MRP3 expression levels and HLA-A24 antigen presence could streamline patient screening for treatment suitability. This would enhance personalized medicine approaches, potentially capturing a significant share of the ~$500M global companion diagnostics market.
🧬 Gene Therapy Platform
Universal T-Cell Gene Modification Technology
The gene introduction technology for patient-derived T-cells could be developed into a versatile platform. This platform could introduce TCRs targeting other cancer antigens or therapeutic genes for genetic diseases, enabling expansion into diverse disease areas within the rapidly growing ~$20B global gene therapy market.
Integration Roadmap — Estimated 36-Month Deployment
Technology Evaluation & Preclinical Planning
Duration: 6 months
Detailed evaluation of the technology's TCR design information and gene introduction protocols. Verification of compatibility with existing cell manufacturing facilities and planning for preclinical trials (animal models).
Clinical Trial Preparation & IND Filing
Duration: 12 months
Establishment of GMP-compliant T-cell manufacturing processes, execution of safety studies, and preparation for Investigational New Drug (IND) application submission to regulatory authorities.
Manufacturing Process Establishment & Approval Application
Duration: 18 months
Collection and analysis of clinical trial data, optimization of manufacturing processes, and preparation for marketing approval application to regulatory agencies (e.g., PMDA).
Technical Feasibility
The claimed TCR protein, its coding sequence, and the method for T-cell introduction can be implemented using existing cell culture and gene transfer technologies (e.g., lentiviral vectors, electroporation). It is not dependent on specialized equipment, and establishing protocols on a general-purpose biomanufacturing platform suggests a relatively low technical integration barrier.
Success Scenario
Implementing this technology could provide a new treatment option for advanced liver cancer patients who are unresponsive to existing therapies. This is expected to maximize therapeutic efficacy, dramatically improve patient quality of life, and contribute to reducing healthcare costs. Licensees could leverage the exclusivity period until 2041 to establish themselves as leading companies in innovative cell therapy.
Patent Record
APPLICATION NO.
特願2021-031740
REGISTRATION NO.
7774284
FILING DATE
2021/03/01
GRANT DATE
2025/11/13
EXPIRATION DATE
2041/03/01
PATENT HOLDER
国立大学法人金沢大学
Examination History
2024年01月29日
出願審査請求書
2025年03月04日
拒絶理由通知書
2025年07月01日
意見書
2025年07月01日
手続補正書（自発・内容）
2025年10月28日
特許査定